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Vitronectin in human hepatic tumours contributes to the
recruitment of lymphocytes in an avb3-independent manner
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The degree of lymphocyte infiltration is a prognostic factor in liver cancer, but to date the mechanisms by which lymphocytes infiltrate
into and are retained in hepatic tumours are poorly understood. We hypothesised that the extracellular matrix glycoprotein
vitronectin, a major component of the stroma of hepatic tumours, might play a role in the recruitment and retention of tumour-
infiltrating lymphocytes (TIL). Thus, we investigated the ability of vitronectin to support migration and adhesion of TIL isolated from
hepatocellular carcinoma and colorectal hepatic metastases. Soluble vitronectin-induced dose-dependent migration of TIL in in vitro
chemotaxis and haptotaxis assays and vitronectin in tissue sections was able to support TIL adhesion to tumour stroma. Neither
adhesion nor migration was inhibited by a function blocking mAb against the major vitronectin receptor avb3 and we were unable to
detect avb3 on TIL in vitro or in vivo on tumour tissue. However, TIL did express high levels of urokinase-type plasminogen activator
receptor (uPAR) and inhibitory antibodies and amiloride both significantly inhibited TIL adhesion to vitronectin and reduced
transendothelial migration of lymphocytes across liver endothelium in vitro. Thus, we provide evidence that vitronectin in liver
tumours can support the recruitment and retention of effector lymphocytes by an uPAR-dependent mechanism.
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Leucocyte recruitment into tissues from blood involves transmi-
gration across the endothelium followed by migration through the
extracellular matrix to sites of inflammation or residence within
tissue. The composition of extracellular matrix differs between
tissues and constitutes an organ-specific microenvironment with
the ability to recruit and retain specific cell types (Hunt et al,
1996). Pathological conditions, including inflammation and cancer
are associated with changes in the composition of extracellular
matrix (Rojkind, 1988), and thus changes in the potential to recruit
or retain inflammatory cells.
Vitronectin, a 75kDa glycoprotein synthesised by hepatocytes,
circulates (Felding-Habermann and Cheresh, 1993) predominantly
as an internally folded and stabilised monomer (Stockmann et al,
1993). A minor fraction undergoes conformational change to adopt
an open heparin-binding reactive form (Preissner, 1991;
McKeown-Longo and Panetti, 1996), which can multimerise and
bind to the extracellular matrix (Johansson, 1996; Francois et al,
1999b). Within the matrix, vitronectin can support cellular
adhesion via interactions with the integrins avb1, avb3, avb5
and aIIbb3 (Preissner, 1991). Vitronectin is found at low
concentrations in normal extracellular matrices, but is increased
in chronic inflammatory liver disease where its deposition in the
sinusoids is indicative of progressive fibrosis (Inuzuka et al, 1992;
Kobayashi et al, 1994; Koukoulis et al, 2001). Vitronectin is also a
major component of the stroma of primary hepatocellular
carcinoma (HCC) and metastatic hepatic tumours, including
colorectal hepatic metastases (CHM) (Jaskiewicz et al, 1993).
Vitronectin has promigratory properties for several cell types,
and by activating avb3, it can promote a4b1-mediated adhesion of
lymphocytes to VCAM-1 (Imhof et al, 1997; Legler et al, 2001).
This may be particularly important in HCC where leucocyte
accumulation cannot be accounted for by local proliferation
because less than 5% of CD3
þ T cells within HCC are actively
dividing (Yoong and Adams, 1998; Yoong et al, 1998), implying
that increased recruitment and retention in the tumour also
contribute.
In the present study, we demonstrate increased expression of
vitronectin associated with areas of lymphocyte infiltration in
chronically inflamed liver and in primary and metastatic tumours.
Furthermore, we show for the first time that vitronectin can
support the adhesion and migration of tumour-infiltrating
lymphocytes (TIL). We conclude that vitronectin plays an
important role in recruiting and positioning lymphocytes within
inflamed and malignant liver tissue.
MATERIALS AND METHODS
Isolation and culture of lymphocytes
Liver issue was obtained from the Liver Unit at the Queen
Elizabeth Hospital with approval from the local Ethics Committee
and consent of patients. Tissues were processed immediately after
resection to extract lymphocytes. Lymphocytes were isolated from
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shepatic tumours and also nonmalignant liver tissue. Tissue was cut
into 5mm
3 pieces, washed in phosphate-buffered saline (PBS) and
digested with 2mgml
 1 collagenase type 1A (Sigma Aldrich Ltd,
Gillingham, UK) under constant agitation at 371C. After 90min,
collagenase was inactivated with 10% FCS (Invitrogen, Paisley,
UK) and the cell suspension was sieved, washed and lymphocytes
enriched on Ficoll–Hypaque (Pharma, Oslo, Norway). When
sufficient numbers of TIL were obtained, they were rested
overnight in the medium without the addition of exogenous IL-2
and used as fresh, unexpanded cells in the migration assays. In
most experiments, the low yield of TIL required us to expand them
in IL-2 before carrying out the functional assays. In these cases, the
TIL-enriched fraction was plated at 0.5 10
6cellsml
 1 in 24-well
plates in RPMI-1640 (Sigma, UK) with 2mML -glutamine,
60mgml
 1 benzylpenicillin, 100mgml
 1 streptomycin and
50ngml
 1 amphotericin plus high-dose rIL-2 1000IUml
 1
(Chiron, Liverpool, UK) and maintained at 371C in a humidified
incubator for up to 20 days. Prior to experimentation, TIL were
transferred to resting medium overnight (RPMI-1640 plus 10%
FCS) to remove exogenous IL-2. Lymphocytes isolated from
nonmalignant tissue specimens (liver-infiltrating lymphocytes
(LIL)) were incubated overnight in resting media and used the
next day for functional assays. Cell viability was tested by Trypan
blue exclusion. Lymphoblasts were generated from peripheral
blood lymphocytes (PBL) by culturing mononuclear cells in 24-
well plates coated with anti-CD3 (10mgml
 1, Dako, High
Wycombe, UK) in RPMI plus high-dose rIL-2 and 10% FCS at
2 10
5cellsml
 1 for 2–3 days.
Immunohistochemistry
Immunohistochemistry was used to detect CD2 (MT910; Dako,
High Wycombe, UK), avb3 (LM609) and vitronectin (MAB1945)
(both from Chemicon International Inc., Temecula, CA, USA)
(Yoong et al,. 1999) in primary HCC and hepatic metastases from
colorectal cancer. Cryostat sections (5mm) were cut from snap-
frozen tissue, fixed in acetone (Fisher Scientific, Loughborough,
UK) and incubated with primary antibody followed by rabbit
anti-mouse immunoglobulin and a species-specific anti-immuno-
globulin antibody conjugated with alkaline phosphatase. Alkaline
phosphatase activity was developed with 0.1% Fast Red substrate
in TBS (pH 8.2) plus N,N-dimethylformamide, napthol AS-MX
phosphate and levamisole (all Sigma). Sections were counter-
stained with Mayer’s haematoxylin (Sigma). Negative controls
were stained with an isotype-matched antibody (Dako). Immuno-
cytochemical analysis of cytospins used the same staining
protocol.
Chemotaxis assay
Lymphocyte chemotaxis was measured in a modified Boyden
chamber (Adams et al, 1994). Freshly isolated TIL or TIL cultured
in high-dose IL-2 was rested overnight in RPMI/10% FCS.
Dilutions of soluble vitronectin (BD Biosciences, Oxford, UK),
CCL5/RANTES (R&D Systems, Oxford, UK) or control buffer were
applied in quadruplicate to lower wells separated by a single 8mm
pore size polycarbonate membrane (Whatman International,
Banbury, UK) from the cell suspension (1.5 10
6cellsml
 1)i n
50ml aliquots to the upper wells. The chamber was incubated for
2h at 371C and nonmigrated cells washed from the upper surface
of the membrane. Migrated cells bound to the lower surface of the
membrane were fixed in methanol and stained with Diff-Quik
(Dade BehringAG, Du ¨dingen, Switzerland). The number of
migrated cells was counted in five high-power fields/well and an
overall average for the four replicates calculated. This average
value was divided by the basal level of migration as defined by the
average number of cells that moved towards a control stimulus to
yield a chemotactic index.
Haptotaxis assay
This assay was designed to investigate whether TIL show migratory
responses to immobilised vitronectin, that is, haptotaxis as well as
chemotaxis or chemokinesis in response to soluble vitronectin
(Hauzenberger et al, 1995). One microlitre of 0.02% BSA/RPMI as a
control and different concentrations of vitronectin also in RPMI
were applied to the surface of glass slides and then the chemotaxis
membranes were coated by floating the membrane on the surface of
the slide with the underside in contact with the coating solution
overnight at 41C. The membranes were carefully lifted off the slide
and the underside washed in PBS and allowed to air dry before being
used in the chemotaxis assay as described in the section above.
Adhesion assays
Tissue-binding assay Adhesion of lymphocytes to liver tissue was
assessed using a tissue-binding assay (Yoong et al, 1998). Cryostat
sections (10mm) of tissue mounted on poly-L-lysine-coated slides
were fixed in acetone and used as a substrate for adhesion.
Antibody blockade was carried out by preincubating the sections or
lymphocytes with blocking mAb for 30min at 371C. For some
experiments, the sections were incubated with function blocking
antibody directed against vitronectin (10mgml
 1) or an isotype-
matched control antibody (mouse IgG, 10mgml
 1, Dako, UK) for
60min at room temperature. Specificity of the vitronectin antibody
was confirmed by ELISA demonstration of binding to purified
recombinant vitronectin, but not fibronectin or collagen (not
shown). Excess unbound antibody was washed from the section
prior to the addition of lymphocytes labelled with CD2 antibody to
allow them to be distinguished from TIL within the tissue. In other
experiments, TIL were incubated with blocking antibody against
avb3 (20mgml
 1; Chemicon, Chandlers Ford, UK) or b2-integrin
chain (4mgml
 1; BD Bioscience, UK) or an isotype-matched
control for 30min at 371C before application to the sections. In
all experiments, lymphocytes were incubated on the sections for
30min before fixing in acetone, washing and immunohistochemical
staining to detect adherent cells. Lymphocyte adhesion was counted
in 10 randomly selected high-power fields in both tumour tissue
and in the associated normal tissue away from the tumour margin.
Adhesion to purified vitronectin Static adhesion assays were used
to assess lymphocyte binding to immobilised purified vitronectin.
Soluble vitronectin (2–0.25mgml
 1) was immobilised in 24-well
plates overnight. Lymphocytes (1 10
6ml
 1) were labelled with
calcein AM (1mM, Molecular Probes, UK) for 15min at 371C prior
to incubation in the vitronectin-coated wells in the presence or
absence of function blocking anti-urokinase-type plasminogen
activator receptor (uPAR) antibody (2.5mgml
 1, Chemicon, UK)
or amiloride (100mgml
 1, Sigma). After 30min, the nonadherent
cells were washed off and adherent cells were measured using a
plate reader.
Flow-based adhesion assays To study the function of uPAR in
lymphocyte transendothelial migration under the influence of
physiological blood flow, primary human hepatic sinusoidal
endothelial cells were cultured from human liver tissue as
described previously (Lalor et al, 2002) and grown to confluence
in glass capillary tubes. They were then stimulated for 24h with
TNF-a and IFN-g (both 10ngml
 1; R&D Systems) and connected
to the flow-based system as described previously (Curbishley et al,
2005). Liver-infiltrating lymphocytes were perfused through
microslides at a physiologically relevant wall shear stress of
0.05Pa. Adherent cells were visualised microscopically under
phase contrast and a video link was used to record assays for off-
line analysis at a later date. The number of adherent cells was
converted to adherent cells per millimetre squared and corrected
for the number of cells perfused. The pattern of adhesion was
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sanalysed to determine the number of cells rolling, statically
adherent or transmigrated. Cells appearing phase bright were
above the endothelial monolayer, whereas those appearing phase
dark had migrated through the monolayer. For functional studies,
HSEC monolayers were incubated with blocking antibodies raised
against uPAR or amiloride as described above for 90min at 371C.
Flow cytometry
FACS was used to phenotype TIL, PBL and the dermal
microvascular endothelial cell line HMEC-1 (a gift of Dr E Ades
(CDC Atlanta, GA, USA)) (Adams et al, 1997). HMEC-1 were
grown as described before. Gentle trypsinisation was used to
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Figure 1 Vitronectin expression is increased in HCC. Immunohistochemical localisation of vitronectin and avb3 integrin in HCC. (A) Staining with an
isotype-matched negative control monoclonal antibody. Extensive vitronectin deposits are located in the tumour stroma (B) and within sinusoidal-type
endothelium (C and D). avb3 Integrin expression was restricted to some vessels within the tumour stroma (E), but was absent on infiltrating lymphocytes
(F), which were identified by expression of CD2 (G).
Expression of vitronectin in hepatic tumours
S Edwards et al
1547
British Journal of Cancer (2006) 95(11), 1545–1554 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sprepare single-cell suspensions for analysis by flow cytometry. Cells
were incubated with human immunoglobulin (Grifols, Cambridge,
UK) to block Fc receptors, suspended at 10
6cells/100ml and
incubated with mAb at predetermined optimal concentrations for
60min followed by a 1:50 dilution of FITC-conjugated F(ab0)2
fragments of rabbit anti-mouse immunoglobulin (Dako) for 45min.
At this stage, HMEC-1 were fixed in 1% paraformaldehyde, whereas
lymphocytes were incubated with 10% normal mouse serum to
minimise nonspecific binding prior to a final incubation with R-
phycoerythrin-conjugated mouse secondary antibodies (Dako) for
60min and fixation in paraformaldehyde. Incubations were at 41C
and followed by two washes with PBS plus 2% FCS and 0.02%
sodium azide. Cells were analysed using a Coulter Epics XL flow
cytometer (Beckman-Coulter, High Wycombe, UK) with a lym-
phocyte gate set to exclude dead cells and debris.
RESULTS
Vitronectin is expressed in liver tumours in association
with infiltrating lymphocytes
In normal liver, vitronectin was restricted to the stroma of portal
tracts and to the subendothelial matrix of central veins. In both
HCC and CHM, strong vitronectin staining was detected in the
tumour stroma. In HCC, sinusoidal-type vessels were positive for
vitronectin (Figure 1B–D) and avb3 was detected on tumour
vessels but not on CD2
þ lymphocytes (Figure 1E–G). In CHM,
vitronectin was absent from vessels and avb3 was detected on
tumour endothelium but not on TIL (Figure 2D–F). In HCC, large
numbers of TIL were seen within the tumour with marked
perivascular cuffing in some areas, whereas in CHM, lymphocytes
were localized to the stroma at tumour margins.
Vitronectin stimulates migration of TIL in vitro
Chemotaxis and chemokinesis Our finding that lymphocytes were
associated with areas of increased vitronectin expression led us to
investigate whether vitronectin might promote the recruitment or
retention of lymphocytes. Lymphocytes were freshly isolated from
tumours, rested overnight and either used without further
stimulation or expanded in IL-2 before testing their ability
to migrate towards soluble vitronectin in chemotaxis assays
(Figure 3). The majority of experiments were performed using
IL-2-expanded TIL, as yields of cells were often insufficient to
allow analysis on unexpanded TIL. However, on three occasions,
we were able to assess the ability of vitronectin to stimulate the
A B
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CD2  
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Figure 2 Vitronectin expression is increased in CHM. Immunohistochemical localisation of vitronectin and avb3 integrin in CHM. (A) Staining with an
isotype-matched negative control monoclonal antibody. Extensive vitronectin deposits are located in the tumour stroma (B) and peritumoral stroma (C).
avb3 Integrin expression was restricted to selected vessels within the tumour stroma (D), but was absent on infiltrating lymphocytes (E), which were
identified by expression of CD2 (F).
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Figure 3 Vitronectin induces chemotaxis and chemokinesis of TILs in vitro.( A) Representative data using TIL freshly isolated from three patients with
HCC demonstrating dose-dependent migration in response to soluble vitronectin (2–0.00002ngml
 1). Data represent mean of four wells at each
concentration point. (B) Representative data using TIL or PBL, which had been cultured in high-dose IL-2 for 3 days prior to the analysis of chemotaxis in
response to soluble vitronectin (0.02–2000ngml
 1). Data represent mean of four wells at each concentration point for each donor. (C) Mean data7s.e.m.
from four experiments using different donor TIL and lymphoblasts showing maximal migration to individual optimal concentrations of soluble vitronectin.
(D) Representative chequerboard analysis of the migration of TIL isolated from one donor towards different concentrations of vitronectin. In order to
determine whether the effect of vitronectin is to drive chemotaxis or stimulate motility, different concentrations of vitronectin were applied to both the
lower and upper wells of the chemotaxis chamber as indicated. Chemotactic indices greater than 2 are highlighted and represent significant migration
compared with control. Data represent mean of four replicates. (E) Vitronectin also induces haptotaxis. Five different TIL preparations are shown migrating
through membranes that have been coated with BSA alone (0mgml
 1 vitronectin) or 0.02 and 2.0mgml
 1 vitronectin. Responses are shown as cells per
high-power field migrating. In all five patients, there was a response to 0.02mgml
 1 vitronectin coating concentration, which did not increase at higher
coating concentrations. In all four panels, values are given as chemotactic index with migration to control buffer assigned a value of 1. Indices greater than 2
indicate significant migration.
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schemotactic activity of freshly isolated TIL (Figure 3A). Tumour-
infiltrating lymphocytes chemotaxis was compared with chemo-
taxis of PBL-derived lymphoblasts cultured under similar
conditions. Chemotactic indices greater than 2 indicate significant
migration when compared with migration to medium alone.
Tumour-infiltrating lymphocytes from both CHM and HCC
showed significant chemotactic responses to vitronectin, which
peaked between 0.2 and 20ngml
 1 (Figure 3B and C). Peripheral
blood lymphocytes from HCC patients showed a similar response
(Figure 3B and C). We used checkerboard analysis to determine
whether vitronectin acts by chemotaxis (migration to a gradient)
or chemokinesis (nondirectional migration in the absence of a
gradient, that is, when concentrations are the same in the upper
and lower chambers). Vitronectin induced both chemotaxis and
chemokinesis because increased migration occurred not only when
the concentration was higher in the lower chambers but also in the
absence of a gradient. The effect was specific because media had no
effect on cell migration (Figure 3D). These migration responses
could not be inhibited using antibody raised against the
vitronectin receptor avb3 (not shown).
0
10
20
30
40
50
Stroma
Tumour
Control
block
Control
*
***
Nontumour liver Tumour
Vitronectin Vitronectin
block
Sinusoids
Portal tracts
B
0
20
40
60
80
100
Stroma
Differentiated tumour
N
u
m
b
e
r
 
o
f
 
a
d
h
e
r
e
n
t
 
T
I
L
Control ICAM-1 block Vitronectin block
DT
DT
S
S
A
Adherent TIL
*
*
×100
×200
Figure 4 Tumour-infiltrating lymphocytes bind to vitronectin in tissue sections. (A) Adhesion of TIL to tumour tissue or surrounding stroma in CHM was
determined using Stamper–Woodruff adhesion assays. Data shown are mean adhesion per microscopic field7s.e.m. from six separate experiments where
liver tissue was pretreated with function blocking antibody raised against ICAM-1 or vitronectin or isotype-matched control antibody. Inset representative
micrographs illustrate the patterns of binding of CD2-labelled, red-stained TIL to differentiated tumour (DT) and stroma (S). (B) The adhesion of TIL to
tumour tissue and autologous nontumour liver tissue in patients with CHM where surrounding noninvolved liver tissue was available for comparison. Data
shown are mean adherent TIL7s.e.m. from three experiments. Tumour-infiltrating lymphocyte binding to CHM is separated into adhesion to vitronectin-
positive stroma regions (S) and vitronectin-negative differentiated tumour regions (DT). Tumour-infiltrating lymphocyte binding to autologous noninvolved
liver tissue is separated into adhesion to vitronectin-positive portal tracts and vitronectin-negative sinusoids. Statistical significance was calculated using paired
t-tests (*Pp0.05, ***Pp0.001).
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sHaptotaxis To investigate whether immobilised vitronectin could
also stimulate migratory responses in TIL, we used an assay of
haptotaxis (migration on an immobilised substrate). Migration to
immobilised vitronectin was compared with migration on
membranes coated with 0.02%. BSA/RPMI. Vitronectin mem-
branes were coated with 0.02 or 2mgml
 1 vitronectin and the
experiment conducted as before (Figure 3E). Tumour-infiltrating
lymphocytes showed increased migration to immobilised vitro-
nectin compared with BSA control, although there was no increase
with the higher coating concentration, suggesting that 0.02mgml
 1
is sufficient for optimal coating of the chemotaxis membranes. The
chemotactic index in response to immobilised vitronectin was 3.23
at 0.02mgml
 1 and 2.85 at 2mgml
 1, which is similar to the level of
response seen with the soluble vitronectin.
Vitronectin supports the adhesion of TIL to tumour tissue
Next, we demonstrated that vitronectin within tumour tissue can
support lymphocyte adhesion using a modified Stamper–
Woodruff tissue-binding assay (Stamper and Woodruff, 1976;
Yoong et al, 1998) on tissue sections of tumours. We compared
adhesion of TIL to stromal areas, differentiated tumour tissue and
surrounding, noninvolved tissue (Figure 4). Tumour-infiltrating
lymphocytes preferentially bound to stromal areas where strong
expression of vitronectin was detected (Figure 4A). Tumour-
infiltrating lymphocyte adhesion to these vitronectin-rich regions
was significantly inhibited by a function blocking antibody against
vitronectin (Figure 4A). Analysis of TIL adhesion to noninvolved
tissue surrounding the tumour revealed that vitronectin supported
36.80
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Figure 5 Tumour-infiltrating lymphocytes do not express the vitronectin receptor avb3. Expression of the vitronectin receptor avb3 was evaluated on
TIL isolated from HCC. Tumour-infiltrating lymphocytes were selected for study when they were showing maximal migration responses to vitronectin.
Tumour-infiltrating lymphocytes were cultured for up to 16 days in high-dose IL-2 and analysed for the expression of the vitronectin receptor avb3 by flow
cytometry (A and B). Flow cytometry dot-plot analysis of avb3 expression on CD56
þ and CD3
þ TIL illustrating that lymphocytes failed to express the
integrin at the cell surface, whereas the control human microvascular endothelial cell line (HMEC-1) is strongly positive (C). (D) Cytospins from another TIL
preparation stained for avb3. HMEC-1 (top panel) but not TIL (middle panel) expressed avb3 and TIL were positive for CD2 (bottom panel).
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sadhesion to portal tracts where vitronectin expression was
confined (Figure 4B). However, consistent with the chemotaxis
experiments, we were unable to block adhesion of TIL to
vitronectin using antibodies against avb3 integrin despite good
blocking with an antibody against vitronectin.
TIL do not express avb3 integrin
The failure of anti-avb3 integrin antibodies to block adhesion or
migration to vitronectin was surprising and led us to analyse avb3
expression on TIL. Tumour-infiltrating lymphocytes that showed
maximal responses to vitronectin in the chemotaxis assay were
analysed by flow cytometry, and despite gating on both CD56
þ
and CD3
þ populations, we were unable to demonstrate avb3
expression on TIL (Figure 5A and B), despite strong staining of
cultured dermal microvascular endothelial cells (HMEC-1;
Figure 6C). Cytospins of TIL were also avb3 negative
(Figure 5D), suggesting that TIL do not express avb3.
TIL express the uPAR, which contributes to TIL adhesion
to vitronectin and transendothelial migration of cells
through liver endothelium (Figure 6)
We then looked for expression of the alternative vitronectin
receptor uPAR, which has been detected on activated lymphocytes
(Nykjaer et al, 1994; Bianchi et al, 1996). Figure 6A shows that TIL
express moderate levels of uPAR, which is absent from freshly
isolated PBL. We then investigated the effect of an anti-uPAR
antibody or the uPAR inhibitor amiloride (Crowley et al, 1993) on
TIL adhesion to immobilised vitronectin and found that both
antibody uPAR and amiloride modestly but consistently inhibited
TIL adhesion to immobilised vitronectin in a static adhesion assay
(Figure 6B). Because vitronectin was detected on the tumour
sinusoidal vessels, we next tested the function of uPAR on freshly
isolated liver-derived lymphocytes (without additional expansion
in IL-2) in flow-based transendothelial migration assays using
primary human sinusoidal endothelial cells (Figure 6C). Under
conditions of flow, the uPAR antibody and amiloride significantly
reduced the levels of transendothelial migration, suggesting that
uPAR can promote migration into the liver as well as migration
and retention within the tumour.
DISCUSSION
In both HCC and CHM, prognosis is better if the tumour is
infiltrated by lymphocytes (Emile et al, 2000; Gervaz et al, 2000;
Okano et al, 2003), suggesting that immune responses partially
contain these tumours. Thus, understanding the mechanisms
involved in lymphocyte recruitment has therapeutic implications
for adoptive immunotherapy as well as elucidating mechanisms of
lymphocyte recruitment to inflamed tissue. Stromal cells and
matrix proteins form the structural framework of an organ, which
is critical for the functioning of resident cells and for the
recruitment, retention and differentiation of cells that traffic
through the tissue (Shimizu and Shaw, 1991). For example, splenic
stroma has recently been shown to affect the function of
infiltrating dendritic cells (Zhang et al, 2004) and gut stroma,
the survival of activated lymphocytes (Sturm et al, 2004). Although
changes in the tissue stroma are likely to be critical in the
development of chronic inflammation, little is known about the
role of matrix in regulating the recruitment and retention of
lymphocytes (Schor et al, 2000).
Many cancers stimulate an inflammatory response associated
with changes in ECM components that recapitulate the changes of
chronic inflammation (Coussens and Werb, 2002). This is
illustrated by demonstration of increased vitronectin in
both chronic inflammatory liver disease and in liver tumours
(Jaskiewicz et al, 1993; Nejjari et al, 2002). In the present study,
CHM were characterised by a stromal reaction around the tumour,
which was heavily infiltrated by lymphocytes associated with
strong staining for vitronectin, whereas the tumour itself did not
express vitronectin and was largely devoid of lymphocytes. In
contrast, vitronectin and infiltrating lymphocytes were detected
both in peritumoural stroma and within the tumour itself,
including on tumour vessels in HCC, where vitronectin is probably
secreted by malignant hepatocytes (Inuzuka et al, 1992). Our
findings confirm that liver cancer recapitulates chronic inflamma-
tory change and suggested to us that vitronectin might play a role
in the recruitment and retention of lymphocytes within tumours.
This is particularly interesting since recent evidence suggests that
proteolytic cleavage of vitronectin is enhanced in HCC to yield
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Figure 6 Tumour-infiltrating lymphocytes isolated from HCC express
uPAR and demonstrate uPAR-dependent adhesion to vitronectin. Tumour-
infiltrating lymphocytes isolated from HCC were cultured for up to 10 days
in high-dose IL-2 and analysed for the expression of uPAR by flow
cytometry. (A) All TIL in a representative experiment expressed uPAR. (B)
When the same TIL were used in an adhesion assay, binding to immobilized
vitronectin was modestly but significantly inhibited by pretreating the
lymphocytes with amiloride (100mgml
 1) or uPAR antibody (10mgml
 1)
for 20min prior to assay. Data represent mean7s.e.m. of four experiments
using vitronectin at concentrations ranging from 0.25 to 2mgml
 1.( C)
Effect of uPAR on the transendothelial migration of liver-infiltrating
lymphocytes across hepatic sinusoidal endothelium under flow. A function
blocking mAb targeting uPAR or amiloride at a concentration of
100mgml
 1 was used to treat LIL (PBL) and HSEC (EC) before the
perfusion of LIL using a flow-based adhesion assay (at 0.05Pa). HSEC were
stimulated with TNF-a and IFN-g for 24h before the assay. Transendothe-
lial migration is shown as the percent of adherent cells that migrated across
the endothelial monolayer under flow. Data represent mean7s.e.m. of
four experiments. Paired samples t-test was used to calculate the statistical
significance for adhesion events between control and treatment groups
(*¼2Po0.05).
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can be used as a marker of disease progression (Paradis et al,
2005).
We isolated lymphocytes from both HCC and CHM (Yoong and
Adams, 1998; Yoong et al, 1998), which were expanded (Seljelid,
1997) in vitro to generate sufficient numbers for functional studies.
We studied their migratory and adhesive interactions with
vitronectin. Tumour-infiltrating lymphocytes migrated towards
soluble vitronectin by chemotaxis at low concentrations and at
higher concentrations stimulated chemokinesis. Migration assays
using immobilised vitronectin demonstrated that TIL also show a
haptotactic response to vitronectin, that is, migration in response
to an immobilised substrate. Thus, soluble vitronectin can act to
direct migration and to stimulate general motility of lymphocytes,
and this response may be further stimulated when the lymphocyte
interacts with immobilised vitronectin in the tumour stroma.
Thus, vitronectin may promote the accumulation of lymphocytes
within the tumour stroma. To our surprise, this migration was not
inhibited by antibodies against the classical vitronectin receptor
avb3, which we were unable to detect on TIL using three different
methods, flow cytometry, immunocytochemistry and immuno-
histochemistry. The molecule was appropriately expressed on an
endothelial cell line. Lack of expression on TIL is consistent with
our previous published work showing a lack of avb3 on TIL
isolated from malignant melanoma (Adams et al, 1997). Other
integrins that can bind vitronectin are not found at high levels on
lymphocytes (Nejjari et al, 2002), but the uPAR, which can either
modulate the function of other integrins or act directly as an
adhesion receptor for vitronectin has been demonstrated on
activated lymphocytes and reported to mediate migration (Nykjaer
et al, 1994; Wei et al, 1994; Bianchi et al, 1996; Blasi, 1997). We
were able to inhibit TIL adhesion to immobilised vitronectin with
anti-uPAR antibodies or the uPAR inhibitor amiloride. Because we
detected strong vitronectin on tumour endothelium in HCC in
sinusoidal-like vessels, we also tested the function of uPAR in
another migration system in which fresh liver-derived lympho-
cytes were tested for their ability to undergo transendothelial
migration across monolayers of human hepatic sinusoidal
endothelium under flow. In this system, antibodies to uPAR and
amiloride both inhibited adhesion and transendothelial migration.
Activated T cells also express the uPA, which binds soluble
vitronectin allowing the complex to activate uPAR (Nykjaer et al,
1994; Preissner et al, 2000; Sidenius and Blasi, 2000). In melanoma
cells, adhesion to vitronectin is enhanced in the presence of uPA,
and soluble uPAR inhibits this effect, indicating that uPA/uPAR
functions as a vitronectin receptor that can promote cell
attachment (Sidenius and Blasi, 2000; Sidenius et al, 2000) In
contrast, plasminogen activator inhibitor I stimulates melanoma
cell migration on vitronectin, presumably either by inhibiting uPA/
uPAR-mediated cell adhesion or by direct effects on the
cytoskeleton (Waltz et al, 1997). Our data suggest that a similarly
complex interaction with vitronectin and the uPA system might
contribute to adhesion and migration of lymphocytes. These
mechanisms may be particularly relevant in the liver because uPA/
PAI-1 and vitronectin are colocalised at areas of inflammatory
damage in liver disease (Inuzuka et al, 1992).
Leucocytes may encounter vitronectin either as a soluble protein
or immobilised within the extracellular matrix or on tumour
vessels. Our data suggest that all of these interactions can stimulate
TIL migration and motility (Francois et al, 1999a; Preissner et al,
2000). In order to determine that native, tissue-bound vitronectin
could mediate direct adhesion of TIL, we used tissue-binding
assays to demonstrate that vitronectin in liver tumours can
support the adhesion of TIL. Tumour-infiltrating lymphocytes
adhesion to the vitronectin-rich stromal regions of hepatic
tumours was blocked using an antibody to vitronectin, but once
again antibodies against avb3 had no effect. We detected TIL
adhesion to the portal tracts in adjacent noninvolved liver tissue,
which was again blocked by antibodies against vitronectin,
suggesting that vitronectin in the native liver can also support
lymphocyte adhesion. Thus, vitronectin can combine with other
adhesive proteins (Yoong et al, 1998) expressed within the tumour
microenvironment to support the recruitment and retention of
lymphocytes within liver tumours and inflamed liver tissue.
Our studies also have implications for chronic inflammatory
liver diseases in which lymphocyte infiltration is associated
with areas of increased vitronectin deposition (Inuzuka et al,
1992; Jaskiewicz et al, 1993; Kobayashi et al, 1994; Koukoulis
et al, 2001).
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